Acute Myeloid Leukemia
Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Cecilia BrownAcute Myeloid Leukemia | December 1, 2022
Nicholas Short, MD, on his hopes for the new year in blood cancer. 
Read More
Leah SherwoodMyeloproliferative Neoplasms | December 1, 2022
The revised classification includes many authors of the prior WHO edition but is not affiliated with the WHO.
Blood Cancers Today Staff WritersAcute Myeloid Leukemia | December 1, 2022
Augment 101 is phase I/II trial investigating revumenib in patients with MLL rearranged or mNPM1 acute leukemias.
Cecilia BrownPrint | November 23, 2022
Eprenetapopt and azacitidine after allogeneic HSCT was well tolerated in patients with TP53-mutated AML and MDS.
Cecilia BrownPrint | November 23, 2022
Baseline genetic characteristics are the primary determinants of allogeneic HSCT outcomes in older adults with AML.
Leah SherwoodAcute Myeloid Leukemia | October 21, 2022
Marina Konopleva, MD, PhD, discusses venetoclax resistance in AML during SOHO 2022
Cecilia BrownAcute Myeloid Leukemia | October 13, 2022
Marina Konopleva, MD, PhD, discusses her new role at the Albert Einstein College of Medicine and highlights from her career ...
Leah SherwoodAcute Myeloid Leukemia | October 12, 2022
Gilteritinib plus induction and consolidation chemotherapy demonstrated acceptable safety outcomes and efficacy in patients ...
Leah SherwoodAcute Myeloid Leukemia | October 10, 2022
Dr. Konopleva spoke to Blood Cancers Today during the 2022 SOHO Annual Meeting.
Kerri FitzgeraldAcute Myeloid Leukemia | October 3, 2022
The efficacy of enasidenib in patients with AML depends on the mutation type.
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
A conditioning regimen of clofarabine plus total body irradiation prior to allogeneic hematopoietic stem cell transplantation ...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
New research suggests venetoclax-containing regimens with intensive treatment and allogeneic hematopoietic stem cell ...
Leah SherwoodAcute Myeloid Leukemia | September 22, 2022
Guillermo Garcia-Manero, MD, gives his perspective.
Cecilia BrownAcute Myeloid Leukemia | September 15, 2022
Wei Wang, MD, PhD, and colleagues conducted the study and published its findings in Cancers.
Leah SherwoodAcute Myeloid Leukemia | August 16, 2022
A second allogeneic hematopoietic stem cell transplantation (HSCT) is a reasonable treatment option for patients with ...
Leah SherwoodAcute Myeloid Leukemia | August 16, 2022
The report showed significant demographic and geographic imbalances in pivotal clinical trials leading to drug approval.
Leah SherwoodAcute Myeloid Leukemia | August 16, 2022
DSP-5336 is an investigational small-molecule inhibitor against the binding of menin and mixed-lineage leukemia protein.
Leah SherwoodMyelodysplastic Syndromes | August 12, 2022
A phase II, multicenter, open-label trial found that eprenetapopt plus azacitidine was well tolerated and safe.
Leah SherwoodMyelodysplastic Syndromes | August 12, 2022
The trial examined selinexor's effect on treatment outcomes in patients with AML and high-risk MDS.
Leah SherwoodMyelodysplastic Syndromes | August 12, 2022
The global, phase III PANTHER trial investigated the comparison in higher-risk MDS, higher-risk CMML, and AML.
Advertisement
Editorial Board

Advertisement